Syndax Pharmaceuticals Profit Margin

The latest profit margin for SNDX is -87.6% as of June 2026. That compares with -428.48% in the prior-year period — up 79.6% year over year. That is below the Healthcare sector average of 13.76%. Investors often review this figure alongside Syndax Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, SNDX's profit margin moved from -428.48% to -87.6% — a 79.6% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Syndax Pharmaceuticals's valuation or profitability profile.

Against Healthcare companies, SNDX currently prints -87.6% for profit margin, while the sector average sits near 13.76%. That is roughly 736.6% below the sector mean. Large gaps often invite a closer look at Syndax Pharmaceuticals's growth, margins, and balance sheet.

Profit Margin shows how effectively Syndax Pharmaceuticals converts resources into returns. At -87.6%, SNDX may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -428.48% in the prior-year period — up 79.6% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting SNDX's profit margin (-87.6%), review year-over-year change from -428.48%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.